Description
Is Reucent XR 15 mg right for your situation?
Review these criteria with your doctor before enquiring- ✓Moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis with inadequate response to prior therapies
- ✓Moderate-to-severe atopic dermatitis in adults or adolescents 12+ uncontrolled by topical therapy
- ✓Moderate-to-severe active ulcerative colitis
- ✓Need a generic alternative to Rinvoq® made by Incepta
- ✗Active serious infection — TB screening mandatory before starting
- ✗History of venous thromboembolism or major cardiovascular events
- ✗Pregnant or planning pregnancy
- ✗Age 50+ with cardiovascular risk factors
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Reucent XR 15 mg?
Reucent XR 15 mg is a generic extended-release formulation of Upadacitinib — a selective JAK-1 inhibitor — manufactured by Incepta Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 15 mg of upadacitinib in an extended-release formulation identical in active content to Rinvoq® (AbbVie), and is dispensed under the Named Patient Program.
Upadacitinib is a small molecule generic — not a biosimilar. It is taken orally once daily.
| Generic name | Upadacitinib |
| Reference brand | Rinvoq® (AbbVie) |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | JAK-1 Selective Inhibitor |
| Dosage form | Extended-release tablet — 15 mg |
| Pack size | 10 tablets per pack |
| Route | Oral · once daily, with or without food |
| Prescription | Required — physician only |
How Upadacitinib Works
In autoimmune conditions, an overactive JAK signalling pathway drives chronic inflammation, causing joint damage, skin inflammation, and systemic symptoms.
What to Expect: First 30 Days
Upadacitinib typically shows faster onset than biologics — many patients notice improvement within 2–4 weeks.
- Before starting: TB screening, blood counts, liver function, and lipid panel are required.
- Weeks 1–2: Early reduction in joint pain, stiffness, and skin symptoms is common.
- Weeks 3–4: Blood counts and lipids are rechecked. Full response assessed at 12 weeks.
Side Effects
Common · Usually Manageable
- Upper respiratory infections
- Nausea / headache
- Acne / folliculitis
- Elevated LDL cholesterol
- Herpes zoster reactivation
Serious · Report Immediately
- Serious or opportunistic infections
- Venous thromboembolism (DVT/PE)
- Major cardiovascular events
- Malignancy
- Hepatotoxicity
- Fever or signs of serious infection
- Leg swelling/pain, chest pain, breathlessness
- Yellowing of skin or eyes
How to Take Reucent XR 15 mg
Standard dose: 15 mg once daily (most indications) · 30 mg once daily for atopic dermatitis/ulcerative colitis induction. With or without food. Do not crush or chew — this destroys the extended-release mechanism.
- 1Once daily, same time each day — with or without food.
- 2Swallow whole with water. Never crush, split, or chew.
- 3Confirm TB screening is done before starting.
- 4If you miss a dose, take it the same day. Skip if nearly time for next dose.
Frequently Asked Questions
Is Reucent XR a biosimilar?
What is the difference between Reucent XR and other upadacitinib brands on this site?
Why is TB screening mandatory?
How do I order Reucent XR through Meds For Cancer?
Meds For Cancer operates as an NPP facilitator. WHO-GMP certified medicines are made available to patients with a confirmed medical need and valid prescription.
- Fleischmann R, et al. SELECT-COMPARE. Ann Rheum Dis 2019;78:1116–1123.
- Guttman-Yassky E, et al. Measure Up 1 and 2. Lancet 2021;397:2151–2168.
- FDA Prescribing Information: Rinvoq (upadacitinib). AbbVie, 2023.
Reviews
There are no reviews yet.